menu toggle
Independence Day
Cencora will be closed in observance of the Independence Day holiday and there will be no deliveries on Thursday, July 4. Our Customer Service and Customer Systems Support teams will also be unavailable on this day. Please review our full holiday schedule for more detailed information and to plan your orders accordingly. We will resume normal operations on Friday, July 5.
Review our full holiday schedule here

Outlook Therapeutics® and AmerisourceBergen Announce Strategic Commercialization Agreement for ONS-5010 for the Treatment of Wet AMD

ISELIN, N.J. and CONSHOHOCKEN, Pa., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, and AmerisourceBergen (NYSE: ABC), a global healthcare company and leader in specialty pharmaceutical distribution and services, announced today that they have entered into a strategic relationship in preparation for the anticipated commercial launch in the United States of ONS-5010 / LYTENAVA™ (bevacizumab-vikg), if approved by the U.S. Food and Drug Administration (FDA).

More in the Media

Addressing Access and Affordability Issues With Collaboration at Asembia 2024

May 06, 2024

Understanding State Regulations and Advocating for Medically Integrated Dispensing

May 03, 2024

Biosimilar Legislation Making Moves in the Right Direction

May 02, 2024

Distributors Play a Role in Patient Access Programs

May 02, 2024